Patents by Inventor Philipp Janser

Philipp Janser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NLRP3 inflammasome inhibitors
    Patent number: 12168012
    Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: December 17, 2024
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela MacKay, Henri Mattes, Nikolaus Johannes Stiefl, Juraj Velcicky
  • NLRP3 inflammasome inhibitors
    Patent number: 12139471
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: November 12, 2024
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20220251067
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: January 13, 2022
    Publication date: August 11, 2022
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
  • NLRP3 inflammasome inhibitors
    Patent number: 11254653
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 22, 2022
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
  • NLRP3 inflammasome inhibitors
    Patent number: 11208399
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: December 28, 2021
    Assignee: Novartis AG
    Inventors: Christopher Farady, Nina Gommermann, Philipp Janser, Angela Mackay, Henri Mattes, Nichola Smith, Catherine Fooks Solovay, Nikolaus Johannes Stiefl, Eric Vangrevelinghe, Juraj Velcicky, Anette von Matt
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20210308140
    Abstract: The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R1, R2 and R3 are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of disease and disorders mediated by NLRP3.
    Type: Application
    Filed: July 23, 2019
    Publication date: October 7, 2021
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nikolaus Johannes STIEFL, Juraj VELCICKY
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20200361899
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: May 15, 2020
    Publication date: November 19, 2020
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
  • NLRP3 INFLAMMASOME INHIBITORS
    Publication number: 20200361898
    Abstract: The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I): wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
    Type: Application
    Filed: May 15, 2020
    Publication date: November 19, 2020
    Inventors: Christopher FARADY, Nina GOMMERMANN, Philipp JANSER, Angela MACKAY, Henri MATTES, Nichola SMITH, Catherine Fooks SOLOVAY, Nikolaus Johannes STIEFL, Eric VANGREVELINGHE, Juraj VELCICKY, Anette von MATT
  • Aryl benzylamine compounds
    Patent number: 8791100
    Abstract: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 28, 2011
    Date of Patent: July 29, 2014
    Assignee: Novartis AG
    Inventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard, Nikolaus Johannes Stiefl
  • Aryl carboxylic acid cyclohexyl amide derivatives
    Patent number: 8354431
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.
    Type: Grant
    Filed: February 18, 2008
    Date of Patent: January 15, 2013
    Assignee: Novartis AG
    Inventors: Rene Hersperger, Philipp Janser, Wolfgang Miltz
  • Chemokine receptor antagonists
    Patent number: 8183366
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
    Type: Grant
    Filed: September 20, 2010
    Date of Patent: May 22, 2012
    Assignee: Novartis AG
    Inventors: Rene Hersperger, Philipp Janser, Emil Pfenninger, Hans J Wuethrich, Wolfgang Miltz
  • ARYL BENZYLAMINE COMPOUNDS
    Publication number: 20110190258
    Abstract: The present invention relates to substituted aryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: January 28, 2011
    Publication date: August 4, 2011
    Applicant: NOVARTIS AG
    Inventors: Daniela ANGST, Birgit BOLLBUCK, Philipp JANSER, Jean QUANCARD, Nikolaus Johannes STIEFL
  • Chemokine receptor antagonists
    Publication number: 20110015180
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
    Type: Application
    Filed: September 20, 2010
    Publication date: January 20, 2011
    Inventors: René Hersperger, Philipp Janser, Emil Pfenninger, Hans Juerg Wuethrich, Wolfgang Miltz
  • Chemokine receptor antagonists
    Patent number: 7858781
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: December 28, 2010
    Assignee: Novartis AG
    Inventors: René Hersperger, Philipp Janser, Emil Pfenninger, Hans Juerg Wuethrich, Wolfgang Miltz
  • Biaryl Benzylamine Derivatives
    Publication number: 20100168079
    Abstract: The present invention relates to biaryl-benzylamine compounds, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Application
    Filed: December 21, 2009
    Publication date: July 1, 2010
    Inventors: Daniela Angst, Birgit Bollbuck, Philipp Janser, Jean Quancard
  • BIARYL SULFONAMIDE DERIVATIVES
    Publication number: 20100029609
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1-R5, R10 and X1-X7 are as defined in the specification.
    Type: Application
    Filed: September 6, 2007
    Publication date: February 4, 2010
    Inventors: Frederic Berst, Philipp Grosche, Philipp Janser, Frederic Zecri, Birgit Bollbuck
  • ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES
    Publication number: 20100016361
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: (I) wherein the variants R and X are defined in the specification.
    Type: Application
    Filed: February 18, 2008
    Publication date: January 21, 2010
    Inventors: Rene Hersperger, Philipp Janser, Wolfgang Miltz
  • 2-aminopyrimidine derivatives and their medical use
    Patent number: 7615562
    Abstract: A compound of formula I or a pharmaceutically acceptable salt, ester or prodrug thereof wherein the variables have the meanings as defined in the specification. Further disclosed are a method of inhibiting IKK activity using a compound of formula I, a method of inhibiting production of TNF using a compound of formula I, a compound of formula I for use as a pharmaceutical, a pharmaceutical composition comprising a compound of formula I, and use of a compound of formula I in the manufacture of a medicament for use as an immunosuppressant or anti-inflammatory agent.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: November 10, 2009
    Assignee: Novartis AG
    Inventors: Birgit Bollbuck, Alastair DenholmMritain, Jörg Eder, René Hersperger, Philipp Janser, Lászlo Révész, Achim Schlapbach, Rudolf Wálchi
  • Hydroxamic acid derivatives
    Patent number: 7589091
    Abstract: Novel hydroxamic acid derivatives, e.g., of formula (I), wherein R1, R2, R3 and R4 are as defined, are found to be useful as pharmaceuticals, e.g., for the suppression of TNF release and the treatment of autoimmune and inflammatory diseases, e.g., multiple sclerosis and rheumatoid arthritis. Methods of making the compounds, novel intermediates, and pharmaceutical compositions comprising the compounds are provided.
    Type: Grant
    Filed: April 8, 2003
    Date of Patent: September 15, 2009
    Assignee: Novartis AG
    Inventors: Philipp Janser, Wolfgang Miltz, Ulf Neumann
  • Chemokine receptor antagonists
    Publication number: 20070155721
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.
    Type: Application
    Filed: February 10, 2002
    Publication date: July 5, 2007
    Inventors: Rene Hersperger, Philipp Janser, Emil Pfenninger, Hans Wuethrich, Wolfgang Miltz